Can Esperion Therapeutics Inc (NASDAQ:ESPR)’s Tomorrow Be Different? The Stock Had Decline in Shorts

Investors sentiment decreased to 1 in 2018 Q4. Its down 0.11, from 1.11 in 2018Q3. It worsened, as 22 investors sold Esperion Therapeutics, Inc. shares while 40 reduced holdings. 23 funds opened positions while 39 raised stakes. 24.06 million shares or 2.18% less from 24.60 million shares in 2018Q3 were reported.
Great West Life Assurance Can invested in 0% or 3,128 shares. Moreover, Trexquant Inv L P has 0.02% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Swiss Bancorp, Switzerland-based fund reported 42,700 shares. Tudor Inv Et Al reported 10,674 shares. Sei Invests holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 19 shares. Hsbc Hldgs Pcl reported 240,590 shares. Northwestern Mutual Wealth Mngmt reported 22 shares. Art Limited Liability Corporation holds 50,443 shares or 0.15% of its portfolio. State Board Of Administration Of Florida Retirement Sys invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Fmr Ltd Company invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Rhumbline Advisers holds 31,583 shares. 25,565 are held by Ameriprise Financial. Metropolitan Life New York stated it has 0.01% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Daiwa Secs Grp Incorporated invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Citigroup invested in 241,087 shares.

The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) registered a decrease of 8.34% in short interest. ESPR’s total short interest was 5.05 million shares in May as published by FINRA. Its down 8.34% from 5.51 million shares, reported previously. With 338,500 shares average volume, it will take short sellers 15 days to cover their ESPR’s short positions. The short interest to Esperion Therapeutics Inc’s float is 23.19%.

The stock increased 1.49% or $0.76 during the last trading session, reaching $51.73. About 481,594 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 39.96% since May 17, 2018 and is downtrending. It has underperformed by 44.33% the S&P500.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.39 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 7 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Esperion Therapeutics had 9 analyst reports since December 13, 2018 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, March 5. JP Morgan upgraded the shares of ESPR in report on Wednesday, March 13 to “Neutral” rating. Cowen & Co maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Friday, March 1. Cowen & Co has “Buy” rating and $94 target. As per Wednesday, March 13, the company rating was upgraded by J.P. Morgan. Northland Capital maintained it with “Buy” rating and $65 target in Friday, March 1 report. The company was maintained on Thursday, March 14 by Chardan Capital Markets.

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: which released: “Esperion to Participate in Upcoming Investor Conferences – GlobeNewswire” on May 10, 2019, also with their article: “Notable Wednesday Option Activity: KEM, ESPR, BAC – Nasdaq” published on May 15, 2019, published: “Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 – Nasdaq” on March 01, 2019. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: and their article: “Esperion up 8% premarket – Seeking Alpha” published on October 26, 2018 as well as‘s news article titled: “Health Care Sector Update for 05/06/2019: ESPR, AXSM, CANF, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” with publication date: May 06, 2019.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.